u/Qwerty_gu ·
Reddit — r/ValueInvesting
· March 15, 2026 at 22:33
· ⬆ 15 pts
· 💬 9 comments
| View on Reddit ↗
AI Summary
Summary
The post presents a bullish thesis on Novo Nordisk, arguing that the market is underestimating the long-term potential of the obesity treatment market and GLP-1 therapies.
The author, u/Qwerty_gu, has conducted their own analysis, resulting in a base case valuation of EUR 47.7 per share, suggesting significant upside from the current price of EUR 33.1.
Quality assessment: This appears to be well-researched DD, as the author mentions writing an equity research report and provides a specific price target, indicating a quantitative valuation was performed.
The market for obesity treatments and GLP-1 therapies is large and growing, with structural long-term demand. The current market price of Novo Nordisk (EUR 33.1) does not fully reflect this long-term growth potential, leading to an undervaluation compared to the author's calculated fair value (EUR 47.7). Novo Nordisk is undervalued because the market underestimates the size and durability of the obesity drug market, presenting a long-term buying opportunity. Increased competition, pricing pressure from payers, unexpected side effects from GLP-1 drugs, or a slowdown in market adoption could invalidate the thesis.